Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.

C.J. van Marrewijk; S. Mujakovic; G.A. Fransen; M.E. Numans; N.J. de Wit; JW Muris; M.G.H. van Oijen; J.B. Jansen; D.E. Grobbee; J.A. Knottnerus; R.J.F. Laheij

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.

Translated title of the contribution: Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.

C.J. van Marrewijk
, S. Mujakovic
, G.A. Fransen
, M.E. Numans
, N.J. de Wit
, JW Muris
, M.G.H. van Oijen
, J.B. Jansen
, D.E. Grobbee
, J.A. Knottnerus
, R.J.F. Laheij

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.
Original language	Undefined/Unknown
Pages (from-to)	215-225
Number of pages	11
Journal	The Lancet
Volume	373
Issue number	9659
Publication status	Published - 2009

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/19150702

Embargoed Document

56
Final published version, 223 KB
Embargo ends: 01/01/2050 00:00 CET

Cite this

van Marrewijk, C. J., Mujakovic, S., Fransen, G. A., Numans, M. E., de Wit, N. J., Muris, JW., van Oijen, M. G. H., Jansen, J. B., Grobbee, D. E., Knottnerus, J. A., & Laheij, R. J. F. (2009). Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. The Lancet, 373(9659), 215-225. http://www.ncbi.nlm.nih.gov/pubmed/19150702

@article{6152263c179941f38bb99ef562b230c6,

title = "Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.",

author = "\{van Marrewijk\}, C.J. and S. Mujakovic and G.A. Fransen and M.E. Numans and \{de Wit\}, N.J. and JW Muris and \{van Oijen\}, M.G.H. and J.B. Jansen and D.E. Grobbee and J.A. Knottnerus and R.J.F. Laheij",

year = "2009",

language = "Undefined/Unknown",

volume = "373",

pages = "215--225",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9659",

}

van Marrewijk, CJ, Mujakovic, S, Fransen, GA, Numans, ME, de Wit, NJ, Muris, JW, van Oijen, MGH, Jansen, JB, Grobbee, DE, Knottnerus, JA & Laheij, RJF 2009, 'Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.', The Lancet, vol. 373, no. 9659, pp. 215-225. <http://www.ncbi.nlm.nih.gov/pubmed/19150702>

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. / van Marrewijk, C.J.; Mujakovic, S.; Fransen, G.A. et al.
In: The Lancet, Vol. 373, No. 9659, 2009, p. 215-225.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.

AU - van Marrewijk, C.J.

AU - Mujakovic, S.

AU - Fransen, G.A.

AU - Numans, M.E.

AU - de Wit, N.J.

AU - Muris, JW

AU - van Oijen, M.G.H.

AU - Jansen, J.B.

AU - Grobbee, D.E.

AU - Knottnerus, J.A.

AU - Laheij, R.J.F.

PY - 2009

Y1 - 2009

M3 - Article

SN - 0140-6736

VL - 373

SP - 215

EP - 225

JO - The Lancet

JF - The Lancet

IS - 9659

ER -